生物活性 | |||
---|---|---|---|
描述 | Lixumistat (IM156) is a newly developed biguanide mitochondrial protein complex 1 inhibitor targeting oxidative phosphorylation (OXPHOS), displaying anti-tumor effects. Lixumistat modulates OXPHOS to mitigate mitochondrial metabolic reprogramming and suppress lung fibrosis. Additionally, Lixumistat inhibits B-cell activation, thereby alleviating symptoms of systemic lupus erythematosus [1][5]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.17mL 0.63mL 0.32mL |
15.86mL 3.17mL 1.59mL |
31.72mL 6.34mL 3.17mL |